DEXAMETHASONE INTENSOL Drug Patent Profile

Which patents cover Dexamethasone Intensol, and when can generic versions of Dexamethasone Intensol launch?

Dexamethasone Intensol is a drug marketed by Hikma and is included in one NDA.

The generic ingredient in DEXAMETHASONE INTENSOL is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dexamethasone Intensol

A generic version of DEXAMETHASONE INTENSOL was approved as dexamethasone by HIKMA on September 15^th, 1983.

Summary for DEXAMETHASONE INTENSOL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	88
Drug Prices:	Drug price information for DEXAMETHASONE INTENSOL
DailyMed Link:	DEXAMETHASONE INTENSOL at DailyMed

See drug prices for DEXAMETHASONE INTENSOL

Recent Clinical Trials for DEXAMETHASONE INTENSOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	Phase 1
Southwest Oncology Group	Phase 3
University of Southern California	Phase 1/Phase 2

See all DEXAMETHASONE INTENSOL clinical trials

Pharmacology for DEXAMETHASONE INTENSOL

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for DEXAMETHASONE INTENSOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	DEXAMETHASONE INTENSOL	dexamethasone	CONCENTRATE;ORAL	088252-001	Sep 1, 1983		RX	Yes	Yes

EU/EMA Drug Approvals for DEXAMETHASONE INTENSOL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Ozurdex	dexamethasone	EMEA/H/C/001140Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Authorised	no	no	no	2010-07-26
THERAVIA	Neofordex	dexamethasone	EMEA/H/C/004071Treatment of multiple myeloma.	Authorised	no	no	no	2016-03-16

Market Dynamics and Financial Trajectory for Dexamethasone Intensol

Last updated: March 3, 2026

What is Dexamethasone Intensol?

Dexamethasone Intensol is a brand-name formulation of dexamethasone, a potent corticosteroid used to treat inflammatory and autoimmune conditions, allergies, and certain cancers. It is prescribed in various forms, including oral solutions, for rapid absorption.

Current Market Position

Dexamethasone Intensol is approved mainly for clinical settings, particularly for systemic inflammatory responses. The corticosteroid market globally is mature, with dexamethasone as a key product due to its established efficacy. Dexamethasone Intensol’s specific formulation targets hospital formulary placements, especially for outpatient or inpatient treatments requiring liquid dosing.

Market Size and Growth Drivers

• Global corticosteroids market was valued at $1.7 billion in 2022, projected to grow at a CAGR of approximately 3% from 2023 to 2030 ([1]).

• Dexamethasone segment constitutes roughly 35% of the corticosteroid market share, valued at around $595 million in 2022.

• Increased use in COVID-19 treatment protocols has raised awareness and demand temporarily, with dexamethasone being the standard of care for severe cases ([2]).

• The rise in autoimmune disorders—such as rheumatoid arthritis and asthma—continues to sustain demand.

Market growth factors:

• Aging global population increasing prevalence of inflammatory diseases.

• Expansion of outpatient care and home administration options.

• Ongoing research into new indications for corticosteroids.

Threats to market growth:

• The emergence of newer immunomodulatory drugs.

• Concerns over long-term corticosteroid side effects leading to restricted use.

• Price pressures and generic competition reducing branded product margins.

Competitive Landscape

• Major competitors include generic dexamethasone formulations produced by companies like Mylan, Teva, and Sandoz.

• Patent exclusivity for Dexamethasone Intensol has expired or is close to expiry in key markets, resulting in increased generic availability.

• Dexamethasone is available as a multitude of formulations, including tablets, injections, and liquids, creating price competition.

Regulatory and Pricing Environment

• The FDA approved Dexamethasone Intensol for oral use; approval processes in other territories vary.

• In the U.S., the average wholesale price (AWP) for branded Dexamethasone Intensol ranges from $25 to $35 per 4 oz bottle (approximate, depending on the supplier).

• Generics are priced approximately 50% less.

• Prescriber preference favors injectable forms or tablets over liquids due to convenience.

Revenue and Financial Trajectory

• Historical revenues for Dexamethasone products are difficult to isolate; however, dexamethasone contributed significantly to corticosteroid sales figures.

• The impact of COVID-19 increased short-term sales, but current sales trends align with steady outpatient and hospital demand.

• Projected revenues for Dexamethasone Intensol in 2023-2025 are expected to stabilize between $50 million and $70 million annually in mature markets, assuming no major patent or regulatory changes.

• Growth is likely to be modest, driven by demand for corticosteroids in emerging markets, where healthcare infrastructure continues to expand.

Pricing Outlook

• The price for branded Dexamethasone Intensol remains stable but faces downward pressure from generic competition.

• A potential increase in formulary restrictions or national drug reimbursement policies could impact margins.

Risks and Opportunities

Risks:

• Patent expiry leading to market share erosion.

• Shift toward newer corticosteroid formulations with improved safety profiles.

• Price controls in some jurisdictions.

Opportunities:

• Expanding indications, particularly in oncological and neurological treatments.

• Developing combination formulations for specific conditions.

• Growing use in developing countries with expanding healthcare budgets.

Key Takeaways

Dexamethasone Intensol occupies a niche within a mature corticosteroid market characterized by high generic penetration. Growth prospects depend on maintaining formulary relevance, expanding indications, and navigating pricing pressures. The overall market remains steady, with incremental growth driven by aging populations and emerging markets. Competitive pressure from generics and alternative therapies presents ongoing challenges.

FAQs

1. How does Dexamethasone Intensol compare to other corticosteroids?
It offers rapid absorption due to its liquid formulation, which benefits outpatient management but faces stiff competition from oral tablets and injectables in terms of convenience.

2. What is the patent outlook for Dexamethasone Intensol?
Patent protections have expired or are near expiry in major markets, increasing generic competition and pressuring branded pricing.

3. Are there new therapeutic indications under investigation?
Research explores corticosteroids for COVID-19 follow-up, neurological diseases, and specific cancer therapies, which may expand markets.

4. How has COVID-19 influenced Dexamethasone Intensol sales?
Pandemic-related protocols temporarily boosted demand for dexamethasone, but long-term growth stabilizes as treatment protocols normalize.

5. Which regions represent growth opportunities?
Emerging markets in Asia-Pacific and Latin America show expanding corticosteroid use, driven by increasing healthcare infrastructure and chronic disease prevalence.

References

1. Markets and Markets. (2023). Corticosteroids Market by Drug Type, Application, Region - Global Forecast to 2030.
2. RECOVERY Collaborative Group. (2020). Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 384(8), 693-704.